Dempze Nancy E Has $420,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Dempze Nancy E cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 800 shares of the biopharmaceutical company’s stock after selling 40 shares during the quarter. Dempze Nancy E’s holdings in Regeneron Pharmaceuticals were worth $420,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after acquiring an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Regeneron Pharmaceuticals by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after acquiring an additional 89,579 shares during the last quarter. Amundi lifted its stake in Regeneron Pharmaceuticals by 3.4% in the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock valued at $979,794,000 after acquiring an additional 52,166 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after acquiring an additional 174,056 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in Regeneron Pharmaceuticals by 2.1% in the first quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock valued at $458,211,000 after acquiring an additional 14,921 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on REGN shares. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Canaccord Genuity Group restated a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research note on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $563.86 on Thursday. The stock has a market cap of $59.76 billion, a P/E ratio of 14.21, a PEG ratio of 1.86 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,024.36. The company has a fifty day moving average price of $573.34 and a 200 day moving average price of $566.14. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned $11.56 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.